

## Creo Medical Group plc

### Significant Shareholders<sup>1</sup>

Name of shareholder	Number of shares	Voting rights (%)
M&G Investments	41,083,836	9.97
Canaccord Genuity <sup>2</sup>	36,167,753	8.77
Baillie Gifford	27,795,238	6.74
Hargreaves Lansdown, stockbrokers (EO)	22,846,245	5.54
River Global Investors	20,507,371	4.98
AXA Framlington Investment Managers	17,066,645	4.14
Amati Global Investors	15,959,536	3.87
Finance Wales Investments	14,376,727	3.49

### Director Shareholdings (excluding options) as at 31 December 2024

Director	Number of shares	Voting rights (%)
Kevin T. Crofton	4,745,666	1.15
John Bradshaw	1,371,082	0.33
Ivonne Cantu	125,000	0.03
Craig Gulliford <sup>3</sup>	1,652,771	0.40
Mr Richard Rees <sup>4</sup>	3,036,540	0.74
Prof. Christopher Hancock	4,824,657	1.17
David Woods	440,255	0.11
<b>Total</b>	<b>16,195,971</b>	<b>3.93</b>

Percentage of AIM Securities not in public hands<sup>5</sup> as at 31 December 2024: 10.53%

Issued Share Capital as at 31 December 2024: 412,148,979

<sup>1</sup> Information obtained from an analysis of Creo Medical's share register (dated 31 December 2024) undertaken on behalf of Creo Medical by Equiniti - RD:ID.

<sup>2</sup> Canaccord Genuity Wealth Management (Inst) – 32,450,000- 7.87%; Canaccord Genuity Wealth Management (ND) - 3,717,753 - 0.90%.

<sup>3</sup> Includes shares held by Craig Gulliford's wife.

<sup>4</sup> Includes shares held by Richard Rees's wife.

<sup>5</sup> Shares not held in public hands is calculated as defined in the AIM Rules for Companies including shares held by related parties together with their associates (each as defined in the AIM Rules for Companies) and shares held by trustees of the Company's employee share schemes.